Valuation — not yet established
No valuation for Verily Life Sciences is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($3.8B) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Verily Life Sciences
Create free account
No card required
Funding history
3 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Mar 2026 | Later Stage VC | $300.0M | ▮ | ▮ |
| Dec 2020 | PE Growth/Expansion | $700.0M | ▮ | ▮ |
| Jan 2019 | PE Growth/Expansion | $1.0B | ▮ | ▮ |
How Verily Life Sciences's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Verily Life Sciences, we compose those signals into the PA Mark — a weighted composite of 1 recent pricing inputs, decayed by age and reset on new rounds. The implied valuation multiplies the mark by shares outstanding. Full methodology →
Frequently asked
- How much has Verily Life Sciences raised?
- Verily Life Sciences has raised $3.8B in total funding across 3 recorded rounds.
- When did Verily Life Sciences last raise?
- Verily Life Sciences last raised in Mar 2026 (Later Stage VC), raising $300.0M.